Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab
Alemtuzumab is usually associated with opportunistic infections. We have treated 67 patients, 8 non-Hodgkin’s lymphoma and 59 chronic lymphocytic leukemia (CLL) with campath. Among CLL patients, 6 used alemtuzumab in first line, alone or with chemotherapy, 41 as consolidation therapy and 11 as salva...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Ferrata Storti Foundation
2008-02-01
|
| coleção: | Haematologica |
| Acesso em linha: | https://haematologica.org/article/view/4768 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|